ArticleEClinicalMedicine2025
Total neoadjuvant therapy integrating long-course radiotherapy with trifluridine/tipiracil for locally advanced rectal cancer: a single-arm, multicenter phase 2 trial.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deep learning-driven MRI radiomics reveals biological subtypes and predicts recurrence risk in rectal cancer.NPJ precision oncology · 2026Article
- Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity.Experimental hematology & oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Total neoadjuvant therapy (TNT) is recommended for locally advanced rectal cancer (LARC) with high-risk factors. The objective of this multi-center phase 2 study is to evaluate the impact of a newly designed TNT consist of TAS-102 concurrent with long-course radiotherapy followed by consolidative TAS-102 and oxaliplatin on the pathological complete response (pCR) rate in patients with LARC. Methods: Patients with LARC were to receive a newly designed TNT consisting of radiotherapy (50 Gy/25 fractions) concurrently with oral TAS-102 (35 mg/m Findings: From September 1, 2022 through January 11, 2024, 50 patients were enrolled and treated; 44 (88%) received surgery. Among all 50 patients, the overall complete response rate (pCR and clinical complete response [cCR]) was 32% (95% confidence interval [CI] 20-47). Among the 44 patients who underwent surgery, the pCR rate was 32% (95% CI 19-48), exceeding the hypothesized standard pCR rate of 13%. The major pathological regression rate was 52% (95% CI 37-68), and the pathological complete lymph node regression rate was 61% (95% CI 45-76). Of the 6 patients who did not receive surgery, 2 achieved cCR followed by observation, 1 was confirmed to have high microsatellite instability and refused surgery, and 3 refused surgery for personal reasons. Grade 3 hematologic toxicity was recorded in 10 patients (20%) and grade 4 in 3 (6%), consisting largely of myelosuppression. Most patients had mild gastrointestinal toxicity; the most common grade 3 and 4 toxicity was diarrhea (14%). No patients had hand-foot skin reactions. Interpretation: We found that TAS-102 concurrent with preoperative radiotherapy led to a high pCR rate (32%) with acceptable toxicity among patients with stage Ⅱ/Ⅲ rectal cancer. Prospective randomized controlled trials comparing fluoropyrimidine-based and TAS-102-based TNT are warranted. Funding: National Natural Science Foundation of China and Shandong Provincial Natural Science Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.